drugset / Trial / NCT01804361

Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes

NCT01804361

Phase 3 Completed 90 enrolled DH Bio Co., Ltd. BTO Pharm. Co., Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine efficacy and safety of Haporine-S eye drop for the patients with moderate to severe dry eye disease in a multicenter phase III clinical trial.

Timeline

Start
2013-03
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporine Peptide 0.05 % Topical
Subject Haporine-S Unknown Topical

Indications